Technical Analysis for NTRA - Natera, Inc.

Grade Last Price % Change Price Change
B 106.76 0.28% 0.30
NTRA closed down 1.88 percent on Friday, May 17, 2024, on 69 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.28%
Calm After Storm Range Contraction 0.28%
NR7 Range Contraction 0.28%
New 52 Week High Strength 0.28%
Overbought Stochastic Strength 0.28%
New 52 Week Closing High Bullish -1.60%
New Uptrend Bullish -1.60%
Calm After Storm Range Contraction -1.60%
New 52 Week High Strength -1.60%
Upper Bollinger Band Walk Strength -1.60%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Natera, Inc. Description

Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization. It also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal DNA in a pregnant mother's blood and a blood sample from the alleged father; and high throughput carrier screening to determine the risk of passing severe genetic diseases on to offspring. Natera sells its tests directly and partner with other clinical laboratories to distribute its tests. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Acid IBD 50 Medical Genetics Medical Test In Vitro Lab Testing Applied Genetics Genetic Diseases DNA Genetic Testing In Vitro Fertilization DNA Paternity Testing Prenatal Testing Severe Genetic Diseases

Is NTRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 108.75
52 Week Low 36.9
Average Volume 1,361,494
200-Day Moving Average 66.19
50-Day Moving Average 93.92
20-Day Moving Average 97.39
10-Day Moving Average 102.20
Average True Range 3.68
RSI (14) 68.35
ADX 27.37
+DI 32.99
-DI 11.37
Chandelier Exit (Long, 3 ATRs) 97.72
Chandelier Exit (Short, 3 ATRs) 94.16
Upper Bollinger Bands 109.66
Lower Bollinger Band 85.13
Percent B (%b) 0.87
BandWidth 25.19
MACD Line 4.20
MACD Signal Line 3.05
MACD Histogram 1.156
Fundamentals Value
Market Cap 12.79 Billion
Num Shares 120 Million
EPS -4.51
Price-to-Earnings (P/E) Ratio -23.61
Price-to-Sales 8.55
Price-to-Book 10.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 109.99
Resistance 3 (R3) 110.36 109.55 109.40
Resistance 2 (R2) 109.55 108.66 109.37 109.20
Resistance 1 (R1) 108.01 108.10 107.61 107.64 109.01
Pivot Point 107.20 107.20 107.00 107.02 107.20
Support 1 (S1) 105.66 106.31 105.26 105.29 103.91
Support 2 (S2) 104.85 105.75 104.67 103.72
Support 3 (S3) 103.31 104.85 103.52
Support 4 (S4) 102.94